Literature DB >> 34796097

Donor Surgical Morbidity in Pediatric Living-Donor Liver Transplant: A Portuguese Experience.

José Pedro Fernandes Dos Santos1, Ricardo Martins1,2, Maria Francelina Lopes1,3.   

Abstract

PURPOSE: Living-donor liver transplant emerged as an alternative treatment for end stage liver disease due to the lack of cadaveric organs availability that met the demand. In Portugal, pediatric living-donor liver transplant (P-LDLT) was initiated in 2001 in Portugal in order to compensate for the scarcity of cadaveric organs for such cases. The aim of this study was to retrospectively analyze the morbi-mortality of the 28 donors included in P-LDLT program performed at Coimbra's Pediatric Hospital (CHUC), a Portuguese reference center.
METHODS: We retrospectively collected pertinent donor data and stratified complications according to Clavien's scoring system.
RESULTS: In total, 28.6% (n=8) of the donors had surgical complications. According to Clavien-Dindo's classification, two donors had major complications (Clavien grade ≥3), four donors had grade 2 complications, and two donors had grade 1 complications. There were no P-LDLT-related mortalities in the present case series. The most common verified complications were biliary tract injuries and superficial incisional infections, which are consistent with the complications reported in worldwide series.
CONCLUSION: These patients from CHUC shows that donor hepatectomy in P-LDLT is a safe procedure, with low morbidity and without mortality.
Copyright © 2021 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition.

Entities:  

Keywords:  Liver transplantation; Living donors; Morbidity

Year:  2021        PMID: 34796097      PMCID: PMC8593358          DOI: 10.5223/pghn.2021.24.6.528

Source DB:  PubMed          Journal:  Pediatr Gastroenterol Hepatol Nutr        ISSN: 2234-8840


INTRODUCTION

Pediatric liver transplantation is the state-of-the-art treatment for children with established or with a high risk of end-stage liver disease (P-ESLD). Pediatric living-donor liver transplant (P-LDLT) has become a viable and feasible strategy that aims to ameliorate the cadaveric organ shortage experienced by health centers around the world. New surgical innovations and the increasing incidence rate of P-ESLD have caused an upsurge in the use of LDLT. The number of required surgeries has increased by 11-fold since 1991, though the number of donors did not follow this tendency [1]. Due to a shortage of cadaveric organs, there is a significant delay in surgical timing, which can be fatal for children. Currently, the donor death rate and surgical morbidity related to pediatric liver transplant are 0.13% and 10-40% [23], respectively. Morbi-mortality in donors is the main obstacle to the use and evolution of LDLT. Assuring donors' safety is the main priority of this major procedure on a healthy individual. The first attempts of pediatric liver transplantation using a living adult donor were reported in 1988 by Raia et al. [4] who described two complete procedures in which both recipients died. In 1989, Strong et al. [5] described the first successful P-LDLT using a graft obtained from an adult. This technique was first described in the Western world; however, it is especially prevalent in Asian countries where organ donation rates from the deceased are very low. Coimbra's Pediatric Hospital (CHUC) is a tertiary academic center that has served as the national reference center for pediatric liver transplant since 1994. P-LDLT has been performed since 2001 [6]. Additionally, CHUC is among the 18 European centers which are integrated in European Reference Network TransplantChild [7]. This paper presents the experiences of clinicians at CHUC regarding donors' surgical morbidity in P-LDLT. A retrospective analysis of surgical outcomes was made and categorized according to the Classification of Surgical Complications by Dindo et al. [8].

MATERIALS AND METHODS

This study was approved by the Ethics Committee of the Faculty of Medicine, University of Coimbra and followed the Institutional and European Commission rules and Helsinki's ethical standards with the use of deidentified and anonymized data for human medical research. A retrospective revision of clinical records from a single institution was performed, analyzing the medical charts of all donors (n=28) who underwent hepatectomy in P-LDLT (recipients under 18 years of age) in CHUC from April 27, 2001 to September 30, 2018. In addition, we collected the pertinent data of recipient-donor pairs included in the pediatric liver transplant database. No donors were excluded from the study. The collected data included characteristics of both the recipient and the donor, such as sex, age, body mass index (BMI), ABO compatibility, date of the procedure, and primary indication for P-LDLT. The surgical and imagiological data collected included the type and volume of graft collected, total liver volume, remnant liver volume (RLV), and postoperative surgical complications, including morbidity and mortality within the first 90 days after donor hepatectomy. Only healthy volunteers aged between 18 and 50 years, who were ABO-compatible with the recipient, had a BMI between 18 and 28 kg/m2 and had no medical or psychiatric illness were considered for donor evaluation. The donors' preoperative study at CHUC followed an established and strict protocol, which included a psychosocial evaluation, health status evaluation, exclusion of metabolic or infectious diseases, study of the hepatic vascular and biliary anatomy, and evaluation of the total liver and graft volumes in order to determine the percentage of RLV. Analytic pre-donation studies include a full blood count and biochemical study, a complete coagulation study, and viral serology. Depending on the receptor's disease, α-1-antitrypsin dosing and plasmatic ceruloplasmin and copper dosing were performed. An imaging study done prior to donor hepatectomy was performed using computed tomography (CT), magnetic resonance imaging (MRI), and angiography with hepatic three-dimensional (3D) anatomical reconstruction. CT angiography with 3D reconstruction was used to minutely analyze the vascular anatomy of the liver. These imagiological studies were also valuable in calculating the total liver and graft volume, which were essential aspects of a complete preoperative study. MRI allowed a detailed evaluation of the biliary tract, and it was useful for the assessment of hepatic steatosis (sensitivity: 81% and specificity: 100%) [9]. Percutaneous hepatic biopsy was done in selected cases (four donors in our series) due to altered hepatic enzymology (n=2), cryptogenic cirrhosis (n=1) and non-described justification (n=1). The decision to include an individual as a donor in the P-LDLT program ultimately depended on the feasibility of the procedure (decided by the surgical team) and the endorsement of the Admissibility Verification Entity (composed by Ethics Committee members). Postoperative surgical complications were graded according to the Clavien-Dindo. Classification of Surgical Complications, which is presented in Table 1 [8]. A major complication is defined as any kind of surgical morbidity with a grade ≥3 based on the Clavien-Dindo classification system.
Table 1

Clavien-Dindo classification of surgical complications

Grade 1Any deviation from normal postoperative care without the need for pharmacological treatment or surgical, endoscopic, and/or radiological interventions. The permitted therapeutic regimens are: drugs such as antiemetics, antipyretics, analgesics, and diuretics; electrolytes; and physiotherapy. This grade also includes wound infections that opened at the bedside.
Grade 2Requiring pharmacological treatment with drugs other than the drugs permitted for grade I complications. Blood transfusions and total parenteral nutrition are also included.
Grade 3Requiring surgical, endoscopic, and/or radiological intervention:
3a: Intervention not under general anesthesia;
3b: Intervention under general anesthesia.
Grade 4Life-threatening complication (including CNS complications)* requiring IC/ICU management:
4a: Single organ dysfunction (including dialysis);
4b: Multiorgan dysfunction.
Grade 5Death of a patient.
Suffix “d”If the patient suffers from a complication at the time of discharge, the suffix “d” (for “disability”) is added to the respective grade of complication. This label indicates the need for a follow-up to fully evaluate the complication.

CNS: central nervous system, IC: intermediate care, ICU: intensive care unit.

*Brain hemorrhage, ischemic stroke, subarachnoid bleeding, but excluding transient ischemic attacks.

Adapted from Dindo et al. (Ann Surg 2004;240:205-13) [8].

CNS: central nervous system, IC: intermediate care, ICU: intensive care unit. *Brain hemorrhage, ischemic stroke, subarachnoid bleeding, but excluding transient ischemic attacks. Adapted from Dindo et al. (Ann Surg 2004;240:205-13) [8].

RESULTS

A total of 28 hepatectomies for P-LDLT were performed. There were no aborted donor operations. Each donor experienced complete recovery after the donation. There were no deaths or need for postoperative donor liver transplant. The number of procedures performed throughout the years can be seen in Fig. 1.
Fig. 1

Pediatric living-donor liver transplant (P-LDLT) procedures from April 2001 to September 2018.

The donor's medical charts and the prospective P-LDLT database (containing the pertinent information of recipient-donor pairs) were analyzed, and several aspects regarding the demographic characteristics of our study population are presented in Table 2.
Table 2

Donor demographics

CharacteristicValue (n=28)
Age (yr)33.6 (18–47)
Sex
Female18 (64.3)
Male10 (35.7)
Body mass index (kg/m2)23.14 (18–31)
Indications for P-LDLT
Biliary atresia11 (39.3)
α-1-antitrypsin deficiency8 (28.6)
Cryptogenic cirrhosis3 (10.7)
Multifocal hepatocarcinoma1 (3.6)
Fetal hepatoblastoma1 (3.6)
Type 1a glycogenosis1 (3.6)
Acute hepatic failure1 (3.6)
Wilson's disease1 (3.6)
Choledochal type I cyst1 (3.6)
Relationship with recipient
Mother18 (64.3)
Father9 (32.1)
Uncle1 (3.6)
ABO incompatibility0
Type of graft
Left lateral sectionectomy20 (71.4)
Left hepatectomy6 (21.4)
Right hepatectomy2 (7.1)
Mean graft volume (cm3)*/Mean remnant liver volume (%)
Left lateral sectionectomy242.7/82.8
Left hepatectomy382.5/67.5
Right hepatectomy841/39.5
Days of hospital stay7.15 (6–12)
Overall postoperative morbidity rate within 90 days8 (28.6)
Postoperative liver insufficiency0
Death0

Values are presented as mean (range), number (%), or number only.

P-LDLT: pediatric living-donor liver transplant.

*Graft volume was obtained pre-operatively in 26 patients with an average of 322 cm3, ranging from 179 cm3 to 1,051 cm3.

†The average remnant liver volume, determined in 24 donors, was 76% (minimum of 35% to a maximum of 89%).

Values are presented as mean (range), number (%), or number only. P-LDLT: pediatric living-donor liver transplant. *Graft volume was obtained pre-operatively in 26 patients with an average of 322 cm3, ranging from 179 cm3 to 1,051 cm3. †The average remnant liver volume, determined in 24 donors, was 76% (minimum of 35% to a maximum of 89%). As Table 2 presents, the female-to-male ratio preponderance was 1.8 and slightly elevated BMI average was observed. The only child who did not have a parental relationship with the donor received the graft from an uncle. The most common indication for P-LDLT was biliary atresia. A total of 28 procedures were done, with left lateral sectionectomy having been the most common one (n=20; 71.4%), followed by left hepatectomy (n=6; 21.4%) and right hepatectomy (n=2; 7.1%). The overall postoperative morbidity rate within 90 days after the donor's hepatectomy was 28.6% (n=8 patients). However, these complications were mainly minor, except for 7.1% of the cases (n=2 with Grade ≥3 complications) (Table 3).
Table 3

Donors' complications according to the Clavien-Dindo classification

ClaviengradeComplicationnRelative %Absolute %
1Partial respiratory insufficiency13.612.6
Paralytic ileum13.612.6
2Bile leakage27.124.8
Superficial incisional infection27.124.8
33aN/A000
3bIncisional hernia13.612.6
44aHemoperitoneum13.612.6
4bN/A000
5N/A000
Total828.6100

N/A: not applicable.

Adapted from Dindo et al. (Ann Surg 2004;240:205-13) [8].

N/A: not applicable. Adapted from Dindo et al. (Ann Surg 2004;240:205-13) [8]. Two patients developed grade 1 complications. One of them developed partial respiratory insufficiency, which was treated with kinesiotherapy and oxygen supplementation. The other patient experienced paralytic ileum that was resolved with conservative treatment. Grade 2 complications occurred in another four donors. Of these, two donors developed post-surgical bile leakage and both were successfully managed with drainage maintenance and antibiotic therapy. The other two donors presented with a superficial incisional infection, which required antibiotics and resuturing with local anesthesia. Major complications were found in two patients. One of the donors developed a postoperative abdominal hernia, which required surgical repair under general anesthesia (Grade 3b). The incisional hernia was detected within the first 90 days after the donation, though the laparorrhaphy was performed after that period. The other donor experienced a hemoperitoneum followed by hypovolemic shock and was immediately taken to the operating room for urgent hemostasis (Grade 4a).

DISCUSSION

Donor safety is a matter of paramount importance in LDLT. Complications arise in up to 40% of the patients within the first year after transplant. However, 95% of procedure-related morbidities is solved within the first postoperative 90 days [3]. Large retrospective series have reported that 21% of donors experience only one complication after the procedure, and 17% develop two or more surgical complications. The most common surgical morbidities after donor hepatectomy are reported in the literature: biliary leak, 36.9%; bacterial infection, 12%; and incisional hernia, 6%. Pulmonary effusion, neuropraxia, and intrabdominal abscess account for 11% of the surgical morbidities has been reported [10]. Our series reports the existence of the same most common complications as the ones reported in the literature, except for neuropraxia or intrabdominal abscess. Although there was a relatively small number of surgeries in CHUC thus far, the donor morbidity rate is comparable with results obtained worldwide. Within the first three months after donation, the verified overall complication rate was 28.6%. However, Abecassis et al. [3] found that surgical morbidities, such as incisional hernia, bowel obstruction, and psychological complications, may develop as late as 5 to 10 years post-transplant. Apart from the small number of surgeries (due to both a low demand for this kind of procedure and the prioritization of cadaveric grafts for pediatric liver transplant), the retrospective analysis of donors' data was also a limitation in this study. The medical charts did not have a complete informative description of some procedure details. Even though donor mortality is a rare event (0.5% for right hepatectomy and 0.1-0.3% for left hepatectomy [23], it should be addressed as a catastrophe as it affects the recipient, the families of both the donor and recipient, and all of the clinicians involved in the LDLT process. From 1999 to 2017, 23 deaths worldwide have been reported [11]. All efforts should be made to minimize the possibility of donor mortality. Accumulated center know- how, full pre-donation study, strict donor selection criteria, new surgical techniques and intra-operative management, and qualified postoperative patient care are crucial to the improvement of donor outcomes [12]. Knowing the overall rate and types of complications and comparing the results from the CHUC case series with the ones reported worldwide is important for a continuous institutional self-evaluation and improvement. In conclusion, LDLT performed in our center is a safe and feasible treatment option for select pediatric cases. It was verified that CHUC's complication rate is lower than the complication rates verified in large series. Therefore, P-LDLT presents as a viable treatment option for selected cases of P-ESLD.
  9 in total

1.  Liver transplantation from live donors.

Authors:  S Raia; J R Nery; S Mies
Journal:  Lancet       Date:  1989-08-26       Impact factor: 79.321

2.  Successful liver transplantation from a living donor to her son.

Authors:  R W Strong; S V Lynch; T H Ong; H Matsunami; Y Koido; G A Balderson
Journal:  N Engl J Med       Date:  1990-05-24       Impact factor: 91.245

3.  Morbidity and mortality of hepatic right lobe living donors: systematic review and perspectives.

Authors:  Pauline Brige; Géraldine Hery; Sophie Chopinet; Anaïs Palen; Daniel Azoulay; Emilie Gregoire
Journal:  J Gastrointestin Liver Dis       Date:  2018-06       Impact factor: 2.008

4.  Complications of living donor hepatic lobectomy--a comprehensive report.

Authors:  M M Abecassis; R A Fisher; K M Olthoff; C E Freise; D R Rodrigo; B Samstein; I Kam; R M Merion
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

Review 5.  Long-term complications of living donor liver transplantation.

Authors:  J F Renz; J P Roberts
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

6.  Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation.

Authors:  Mary E Rinella; Richard McCarthy; Kiran Thakrar; John Paul Finn; Sambasiva M Rao; Alan J Koffron; Michael Abecassis; Andres T Blei
Journal:  Liver Transpl       Date:  2003-08       Impact factor: 5.799

7.  Donor morbidity after living donation for liver transplantation.

Authors:  Rafik M Ghobrial; Chris E Freise; James F Trotter; Lan Tong; Akinlolu O Ojo; Jeffrey H Fair; Robert A Fisher; Jean C Emond; Alan J Koffron; Timothy L Pruett; Kim M Olthoff
Journal:  Gastroenterology       Date:  2008-04-22       Impact factor: 22.682

8.  Living-donor liver transplantation: donor selection criteria and postoperative outcomes. A single-center experience with a 10-year follow-up.

Authors:  A Lauterio; C Poli; C Cusumano; S Di Sandro; M Tripepi; I Mangoni; P Mihaylov; G Concone; A Giacomoni; L G De Carlis
Journal:  Transplant Proc       Date:  2013-09       Impact factor: 1.066

9.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.